
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MY006
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : $37.0 million
Deal Type : Financing
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006
Details : The funding will allow Mabylon to advance its lead program MY006, a tri-specific antibody for the prophylactic treatment of peanut allergy.
Product Name : MY006
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
August 12, 2025
Lead Product(s) : MY006
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : $37.0 million
Deal Type : Financing
